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Abstract: Glycopeptides of hMOG(30-50) containing aglucosyl moiety on the side-chains of Asn, Ser or Hyp 
at position 31 were synthesised. Antibody titres to hMOG(30-50) and to its glucoderivatives were measured by 
EL1SA in sera of patients affected by different neurological diseases. Anti-hMOG(30-50) antibodies were 
detected only using the glycopeptide [Asn3X(N-GIc)]hMOG(30-50). © 1999 Elsevier Science Ltd. All rights reserved. 
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MS ~ is a human demyelinating disease of the CNS whose pathogenesis has not been yet elucidated. 
An autoimmune mechanism against he prominent CNS myelin Ags is thought o contribute to the 
immunopathogenesis of this disease, even if the target Ags responsible for this inflammatory and 
demyelinating response remain elusive. 
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Although specific responses to the major myelin Ags such as MBP and PLP are likely to be 
important in the course of MS, they may not represent the primary auto-Ags triggering the autoimmune 
response in this disease. It has been recently reported that autoimmune r cognition of quantitatively 
minor myelin components, uch as MOG, could play a relevant role in the initiation and progression of 
MS. 
MOG has been detected only in the CNS of mammalians and it accounts for about 0.01-0.05% of 
total myelin proteins. It is a unique member of the Ig superfamily because it possesses two potential 
t~ansmembrane domains and one N-linked glycosylation site on Asn 31, but the nature of the linked 
glycosyl moiety is still unknown. 
MOG exposure on the outermost surface of myelin makes it an ideal target antigen for Ab- 
recognition. Immunisation with purified or recombinant MOG and corresponding synthetic peptides 
can induce strong immune responses associated with extensive CNS inflammation and demyelination 
in rodents) In the common marmoset Callithrix jacchus MOG induces a relapsing-remitting form of 
EAE characterised by extensive plaque-like demyelination similar to the human disease MS. 3 It was 
previously reported a predominant T cell response to MOG in the peripheral blood of MS patients. 4 In 
contrast, only few and controversial data about anti-MOG Abs are reported in MS patients and no data 
are available using MOG peptides as antigens. 5 
Post-translational modifications of proteins, such as glycosylation, may dramatically affect their 
antigenic properties. Several glycoproteins as, for example, fibronectin expose to Abs discontinuous 
epitopes that may involve glycosylation sites. There are evidences of Abs recognising neither peptide 
nor carbohydrate p r  se, but rather they are directed to a specific peptide conformation i duced by 
glycosylation. 6 The difficulty to fmd MOG Abs in humans could be related to the fact that the human 
antigen is a glycosylated epitope with a well-defined conformation. 
The peptide MOG(35-55) is the immunodominant portion of MOG for both T and B cell responses 
in different animal strains. 7 Anti-MOG(35-55) Abs in Lewis rats strongly reacted against the sequence 
37-46. 8 As position 31 is the unique glycosylation site of native MOG, 9 we decided to synthesise 
glycopeptides of hMOG(30-50). This peptide, containing the immunodominant epitope and the native 
glycosylation site, was modified by introducing an N- or O-linked [3-D-glucopyranosyl residue. In first 
instance, we chose to introduce the glucosyl moiety by different covalent bonds, changing the amino 
acid in position 31 from an Asn to a Ser and a Hyp, in order to verify whether the Ab-response was 
influenced only by the increased hydrophilicity of the glycopeptide or by different conformations. In 
particular, Hyp could provoke a significant change in the final conformation of the glycopeptide, 
because of its rigid and planar conformation. 
Results and Discussion 
In order to detect by ELISA ~° the presence of anti-MOG peptide-Abs in sera of patients affected by 
MS and other neurological diseases, tl we synthesised the wild-type peptide hMOG(30-50) (MOG1) 
and ttuee corresponding N- and O-linked glycopeptides, i.e. [Asn31(N-Glc)]hMOG(30-50) (MOG2), 
[Ser31(O-Glc)]hMOG(30-50) (MOG3) and [Hyp31(O-Glc)]hMOG(30-50) (MOG4), as putative 
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antigens (Table 1). The three glycopeptides were chosen in term of the different covalent bond between 
the glucosyl moiety and the side chain of the amino acid introduced in the sequence at position 31. In 
fact, whereas MOG2 contains an N-glucosyl moiety on Asn (amide bond), as in the native protein, 
MOG3 and MOG4 contain an O-glucosyl moiety on a Ser or a Hyp, respectively (ether bond). 
Table 1 
Amino acid sequences of the hMOG(30-50) peptide derivatives 
Peptide Sequence 
MOG 1 H-Lys-Asn-A•a-Thr-G•y-Met-G•u-Va•-G•y-Trp-Tyr-Arg-Pr•-Pr•-Phe-Ser-Arg-Va•-Va•-His-Leu-•H 
MOG2 H-Lys-Asn(N-G•c)-A•a-Thr-G•y-Met-G•u-Va•-G•y-Trp-Tyr-Arg-Pr•-Pr•-Phe-Ser-Arg-Va•-Va•-His-Leu -O  
MOG3 H-Lys-Ser(O-Glc) -Ala-Thr-Gly-Met-Glu-Val-Gly-Trp-Tyr-Arg-Pro-Pro-Phe-Ser-Arg-Val-Val-His-Leu-OH 
MOG4 H-Lys-Hyp(O-Glc) -Ala-Thr-Gly-Met-Glu-VaI-Gly-Trp-Tyr-Arg-Pro-Pro-Phe-Ser-Arg-Val-Val-His-Leu-OH 
Table 2 
Chemical data of the hMOG(30-50) peptide derivatives 12'13 
Peptide Gradients at 3 mL min 4 for Yield(%) ESI-MS [M+H] ÷ Rt (min) a
semi-prep. HPLC Found (Calc.) 
MOG1 hMOG(30-50) 25-40% B m 30 min 12.5 
MOG2 Asn3~(N-GIc)hMOG(30-50) 20-45% B in 75 min 10.7 
MOG3 Ser3)(O-Glc)hMOG(30-50) 10-60% B in 60 min 18.0 
MOG4 Hyp3t(O-GIc)hMOG(30-50) 10-60% B in 60 min 20.0 
'Analytical HPLC gradients atI mL min4: b30-40% B in 7 min; c10-60% B in 15 min. 
2445 (2444.2) 9.2 b 
2606 (2605.4) 8.8 b 
2579 (2578.4) 10.50 
2606 (2605.4) 8.3 c 
( 'hemistry 
Glycosylation of peptides can be achieved irectly on the resin, ~4 but the building-block approach is 
the most versatile and general method for the preparation of a large variety of glycopeptides with well- 
defined and predetermined structures. ~ 5 The syntheses of the new glycopeptides were performed by the 
solid phase methodology, following the Fmoc/tBu strategy by introducing the three different 
glucosylated building blocks at position 3 I. To this aim we synthesised N%Fmoc-N4-(2,3,4,6-tetra-O - 
acetyl-13-D-glucopyranosyl)-Asn-OPfp, 16 N%Fmoc-O3-(2,3,4,6-tetra-O-benzoyl_[3.D.ghicopyranosyl)_ 
Ser-OPfp 17 and N%Fmoc-Oa-(2,3,4,6-tetra-O-benzoyl_13_D.glucopyranosyl).Hyp.OPfp. 18 All the 
glucosylated building blocks were purified by FCC (AcOEt/hexane 1 : 1.5) in order to obtain pure 13 
anomers to be used for the synthesis of the glycopeptides (Table 2). 
Biology 
The Ab titres against MOG1 and its glycoderivatives were compared in the sera of ten patients. No 
Ab response was detected using the non-glucosylated peptide MOGI. In contrast, Ab reactivity to the 
glycosylated peptide MOG2 was found in sera of patients affected by MS as well as other neurological 
diseases (Fig. 1), 1° but not in sera collected from normal blood donors (data not shown). The 
observation that high Ab titres could be detected by using MOG2, but not MOG3 and MOG4 as 
antigens (Fig. 1 and Fig. 2), indicated that the Ab response to the glycopeptide MOG2 is not an 
unspecific phenomenon due to the presence of the glucosyl moiety. These data suggest hat the Abs 
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detected by MOG2 recognise a glycopeptide epitope and that the different covalent bond between the 
glucosyl moiety and the side chain of the amino acid dramatically affects the Ab recognition. 
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Fig 1: Ab-titre to hMOG(30-50) and its glycopeptides in 
sera of: 5 MS, 2 Myel./Enc., 1ALS and 2 GBS patients. 
Data re expressed asmean values. 
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Fig. 2: Ab-titre to hMOG(30-50) and its glycopeptides in 
sera of 5 MS patients. Data re expressed asmean values. 
These results demonstrate, for the first time, the possibility to identify anti-MOG peptide Abs in 
humans and suggest hat the use of the synthetic glycopeptide [Asn31(N-Glc)]hMOG(30-50) as an 
antigen in ELISA may represent a simple experimental system to investigate auto-reactive Ab 
responses in hutnan diseases of the nervous system. Other MOG peptides or other carbohydrate 
derivatives may reveal additional epitopes recognised by MS auto-Abs. 
In any case [Asn31(N-Glc)]hMOG(30-50) is the first synthetic antigen able to detect anti-MOG 
peptide Abs in 40% of an unselected MS group of patients, as well as in some other neurological 
diseases. The follow-up of the Ab titre to hMOG(30-50) during the evolution of MS would be helpful 
to clarify the autoantibody pathogenic role. 
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